Confo Therapeutics, VIB-VUB spin-off and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554. It is being developed as a non-opioid approach to the treatment of neuropathic pain, a debilitating condition caused by damage to the nerves outside of the brain and spinal cord, for which current treatment methods are often insufficiently effective and can lead to serious side effects and addiction.
